Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Deferoxamine (mesylate) [138-14-7]

Deferoxamine (mesylate) [138-14-7]

Drucken Drucken
Melden Sie sich an
Mindestbestell 2

Katalog-Nummer HY-B0988-20mg

Size : 20mg

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790

Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Deferoxamine mesylate Chemische Struktur

Deferoxamine mesylate Chemische Struktur

CAS. Nr. : 138-14-7

This product is a controlled substance and not for sale in your territory.

Based on 232 publication(s) in Google Scholar

Other Forms of Deferoxamine mesylate:

  • Deferoxamine Angebot einholen
  • Deferoxamine mesylate (Standard) Angebot einholen

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Mar 4;8(9):eabm1896.  [Abstract]

    PAI1 mRNA expression in iHUVEC treated with increasing doses of either CoCl2, Deferoxamine (DFO), 1, 4-DPCA or DMOG.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    The specific inhibitor of ferroptosis Fer-1 (100 μM) and Lip-1 (5 μM), and the iron chelator Deferoxamine (DFOM;100 μM) restored the cellular activity of RAW264.7 macrophages after treatment for 24 h.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    Deferoxamine (DFOM; 100 μM; 24 h) attenuated the abnormal increase of ROS and LPO in macrophages elicited by CdTe QDs.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    H1299 cells are treated with Curcumenol with or without Deferoxamine (DFO; 20 μM) for 24 h, and the cell viability is analyzed.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    The expression of ferroptosis-related proteins in lung cancer cells is detected after Curcumenol treatment with or without Deferoxamine (DFO; 20 μM) by western blotting.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Mar 8;8(10):2004680.  [Abstract]

    Deferoxamine (DFO; 0.5 μM; for 48 h) could rescue iron overload‐induced cell death in both iHep‐Orgs and iHep.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jun;11(6):1513-1525.  [Abstract]

    Deferoxamine (DFO; 10 μM; 72 h) can markedly reverse the cell growth prevented by a2 in MGC-803 and MKN-45 cells.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Jun 23;40(1):206.  [Abstract]

    Propidium iodide staining confirmed that DFO inhibited metformin-induced cell death in T47D cells Deferoxamine (20 μM; 48 h).

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 May 8;5(1):51.  [Abstract]

    Representative results of wound healing after the treatment with the combination of ferroptosis inhibitor DFO and erianin. The expression of EMT markers E-Cadherin and N-Cadherin are examined by western blotting.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119.  [Abstract]

    The cell death induced by the treatment with β-elemene and cetuximab in KRAS mutant CRC cells is almost completely blocked by treatment with ferroptosis rescue agents Deferoxamine (DFO; 20 nM; 24 h), Liproxstatin-1 (Lip-1) or Ferrostatin-1 (Fer-1).

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein is assessed by western blot. Protein levels of FPN1 and hepcidin1 in the liver. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloaded

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein was assessed by western blot. Protein levels of TfR1, FTH1 and FPN1 in the tibia. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloade

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Cell Res. 2018 Dec;28(12):1171-1185.  [Abstract]

    The FTL- or FTH1-knockdown A375 cells are pretreated with or without DFO (50 μM) for 2 h before CCCP stimulation. The pyroptotic morphology and LDH release are indicated.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6180-6189.  [Abstract]

    Quantitative analyses confirm the steady increase of blood vessels over the course of implantation of DFO-loading Gp gel.

    Alle HIF/HIF Prolyl-Hydroxylase Isoform-spezifische Produkte anzeigen:

    Alle Isoformen anzeigen
    HIF-1α HIF

    Alle Akt Isoform-spezifische Produkte anzeigen:

    Alle Isoformen anzeigen
    Akt Akt1 Akt2 Akt3
    Beschreibung

    Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].

    In Vitro

    Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells[1].
    Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels[2].
    Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs[3].
    Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs[3].
    Deferoxamine mesylate (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs[3].
    Deferoxamine mesylate (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Deferoxamine mesylate Related Antibodies

    Western Blot Analysis[1]

    Cell Line: MEFs cells
    Concentration: 1 mM
    Incubation Time: 16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
    Result: Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions.
    Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

    Western Blot Analysis[2]

    Cell Line: HepG2 cells
    Concentration: 100 µM
    Incubation Time: 24 h
    Result: Showed a twofold increase of InsR mRNA levels in cells.
    Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.

    Cell Proliferation Assay[3]

    Cell Line: TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))
    Concentration: 5, 10, 25, 50, 100 µM
    Incubation Time: 7 days (TAMSCs); 9 days (BMMSCs)
    Result: Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 µM dose.

    Apoptosis Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 5, 10, 25, 50, 100 µM
    Incubation Time: 7 days
    Result: Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.

    Western Blot Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 10 µM
    Incubation Time: 3 days
    Result: Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.

    Cell Autophagy Assay[4]

    Cell Line: SH-SY5Y cells
    Concentration: 100 µM
    Incubation Time: 24 h
    Result: Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection.
    Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.
    In Vivo

    Deferoxamine mesylate (6.57 μg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice[1].
    Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)[1].
    Dosage: 6.57 µg/per (10 uL of 1 mM)
    Administration: Drip-on; once daily for 21 days.
    Result: Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.
    Animal Model: Male Sprague-Dawley rats (180-200 g)[2].
    Dosage: 200 mg/kg
    Administration: Intraperitoneal injection; daily for 2 weeks.
    Result: Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.
    Klinische Studie
    Molekulargewicht

    656.79

    Formel

    C26H52N6O11S
    CAS. Nr.

    138-14-7
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O.CS(=O)(O)=O
    Versand

    Room temperature in continental US; may vary elsewhere.
    Speicherung

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Lösungsmittel & Löslichkeit
    In Vitro: 

    H2O : ≥ 200 mg/mL (304.51 mM)

    DMSO : 100 mg/mL (152.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.5226 mL 7.6128 mL 15.2256 mL
    5 mM 0.3045 mL 1.5226 mL 3.0451 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molaritätsrechner

    • Verdünnungsrechner

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 5.56 mg/mL (8.47 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Reinheit & Dokumentation

    Purity: 99.94%

    SDS (393 KB)

    COA (241 KB) HNMR (291 KB) RP-HPLC (251 KB) MS (69 KB) Elemental Analysis Report (99 KB)

    Handling Instructions (2659 KB)
    Verweise

    • [1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e.  [Content Brief]

      [2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47.  [Content Brief]

      [3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64.  [Content Brief]

      [4]. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205.  [Content Brief]

      [5]. Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26(11):3255.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 1.5226 mL 7.6128 mL 15.2256 mL 38.0639 mL
    5 mM 0.3045 mL 1.5226 mL 3.0451 mL 7.6128 mL
    10 mM 0.1523 mL 0.7613 mL 1.5226 mL 3.8064 mL
    15 mM 0.1015 mL 0.5075 mL 1.0150 mL 2.5376 mL
    20 mM 0.0761 mL 0.3806 mL 0.7613 mL 1.9032 mL
    25 mM 0.0609 mL 0.3045 mL 0.6090 mL 1.5226 mL
    30 mM 0.0508 mL 0.2538 mL 0.5075 mL 1.2688 mL
    40 mM 0.0381 mL 0.1903 mL 0.3806 mL 0.9516 mL
    50 mM 0.0305 mL 0.1523 mL 0.3045 mL 0.7613 mL
    60 mM 0.0254 mL 0.1269 mL 0.2538 mL 0.6344 mL
    80 mM 0.0190 mL 0.0952 mL 0.1903 mL 0.4758 mL
    100 mM 0.0152 mL 0.0761 mL 0.1523 mL 0.3806 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Deferoxamine mesylate Related Classifications

    Help & FAQs

    Keywords:

    Deferoxamine138-14-7Desferrioxamine B DFOMAutophagyHIF/HIF Prolyl-HydroxylaseReactive Oxygen SpeciesApoptosisAktHypoxia-inducible factorsHIFsHIF-PHPKBProtein kinase Bdiabetes mellitusneovascularizationcancerAlzheimer’s diseaseMEFsTAMSCsBMMSCsCOVID-19PDSH-SY5YInhibitorinhibitorinhibit